Drug intelligence / Profile preview

serplulimab + SOX

Development stage: Unknown
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Serplulimab + SOX is a combination therapy consisting of serplulimab (an anti-PD-1 monoclonal antibody) and SOX chemotherapy regimen (S-1 + oxaliplatin). Serplulimab works by blocking the PD-1 receptor on T cells, enhancing immune response against cancer cells. The SOX component includes S-1 (an oral fluoropyrimidine) and oxaliplatin (a platinum-based agent) that inhibit DNA synthesis and replication in cancer cells. This immunotherapy-chemotherapy combination is being investigated primarily for the treatment of locally advanced gastric cancer and adenocarcinoma of the esophagogastric junction.

Targets

TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on serplulimab + SOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on serplulimab + SOX.

Explore the full profile